Popular Filters
Trials for Alopecia Areata Patients
Janus Kinase (JAK) Inhibitor
Baricitinib for Pediatric Hair Loss
This trial is testing baricitinib, a medication that may help treat severe hair loss. It targets children aged 6 to less than 18 years who have significant hair loss. The medication works by reducing the immune system's activity that causes hair loss.
JAK Inhibitor
PF-06651600 for Alopecia Areata
This trial is testing a new drug to treat alopecia areata, which is an autoimmune disease that causes hair loss. The trial is open-label, which means all patients will receive the active drug. There is also a sub-study evaluating the immune response to vaccines in patients who have received the drug for at least 6 months.
Cellular Regenerative Treatment
Cell + Plasma Therapy for Hair Loss
This trial is testing a new mixture of cells and plasma to see if it is safe and effective in treating hair loss. The mixture will be compared to a similar mixture and to a control group who will receive a standard treatment.
Trials for Male Pattern Baldness Patients
Biological
Platelet Rich Plasma for Male Pattern Baldness
The injection of autologous platelet rich plasma (PRP) is a relatively novel therapy, generating interest across a wide variety of medical specialties, such as orthopedics, dentistry, ophthalmology, and dermatology. Several recently published studies have demonstrated efficacy in treating androgenetic alopecia (aka male or female patterned hair loss), but each varies in the treatment protocol, and there is no evidence-based data to date guiding the dosing parameters of and intervals between injection sessions. We propose a single-center, single-blinded randomized pilot trial to investigate the most beneficial number and frequency ('schedule') of necessary PRP injections in men and women with androgenetic alopecia.
Low Level Laser Therapy
Theradome LH80 PRO for Male Pattern Baldness
This is a prospective, randomized double-blind, multi-center study to evaluate the efficacy of low level laser therapy over-the-counter at home device Theradome LH80 PRO, compared to SHAM for promoting hair growth in males diagnosed with androgenetic alopecia, and a usability study to assess subject ability to self-assess hair loss and understanding use of the device.
Procedure
Microneedling for Male Pattern Baldness
Androgenetic Alopecia is the most common non scarring alopecia worldwide. Treatment of which has been limited with few options for medical and surgical treatment, the cost of the latter being prohibitive for many. Recently there have been several new modalities proposed as treatment, namely Microneedling and Platelet Rich Plasma. Microneedling has been shown to overexpress hair growth factors which may enhance or stimulate miniaturized hairs to grow. It has also been shown to increase the absorption of topical products significantly. The exact mechanism of action of Microneedling is still being delineated. In this study, we aim to do a half lesional study with global photographs and hair counts done at the start of , week four and week twelve. Patients would be needled once weekly after application of topical anaesthetic (5% EMLA). If by week six there is significant regrowth (\>30%), then total lesional needling will be done. Patients will only be using topical 5% Minoxidil throughout the study as this will prolong the effects of the regrowth.
Phase 3 Trials
Janus Kinase (JAK) Inhibitor
Baricitinib for Pediatric Hair Loss
This trial is testing baricitinib, a medication that may help treat severe hair loss. It targets children aged 6 to less than 18 years who have significant hair loss. The medication works by reducing the immune system's activity that causes hair loss.
JAK Inhibitor
PF-06651600 for Alopecia Areata
This trial is testing a new drug to treat alopecia areata, which is an autoimmune disease that causes hair loss. The trial is open-label, which means all patients will receive the active drug. There is also a sub-study evaluating the immune response to vaccines in patients who have received the drug for at least 6 months.
Janus Kinase (JAK) Inhibitor
Baricitinib for Alopecia Areata
This trial is testing baricitinib to see if it is safe and effective for adults with severe hair loss due to alopecia areata. The drug works by calming the immune system to prevent it from attacking hair follicles. Baricitinib was approved by the FDA for treating severe alopecia areata.
JAK Inhibitor
CTP-543 for Alopecia Areata
This trial is testing CTP-543, a medication that may help people regrow hair by stopping the immune system from attacking hair follicles. It focuses on adults with chronic, moderate to severe alopecia areata. CTP-543 has shown promise in treating this condition.
Trials With No Placebo
Procedure
Mosaic Laser Treatment for Skin and Hair Conditions
This trial is testing a laser treatment called the Mosaic Ultra 1550nm system. It aims to help people with skin problems like wrinkles, scars, and acne. The laser works by boosting the skin's natural healing process to make it look smoother and younger. The 1550 nm laser device has been previously studied for its safety and effectiveness in improving wrinkles, pigmentation, and skin texture.
Behavioural Intervention
Cold Cap Therapy for Chemotherapy-Induced Hair Loss in Children
This trial will test if the Paxman scalp cooling device is safe and effective in preventing hair loss in pediatric patients receiving chemotherapy for non-cancerous conditions or solid tumors.
View More Related Trials
Frequently Asked Questions
Introduction to androgenetic alopecia
What are the top hospitals conducting androgenetic alopecia research?
Hair loss is a common concern for many individuals, particularly those experiencing androgenetic alopecia. Fortunately, several top hospitals are dedicated to unraveling the mysteries of this condition through clinical trials. In New york City, the Icahn School of Medicine at Mount Sinai leads the way with six ongoing trials focused on androgenetic alopecia and a commendable record of 15 previous studies. Their first recorded trial dates back to 2015, showcasing their commitment to finding effective treatments for hair loss. Meanwhile, ForCare Clinical Research in Tampa has made significant strides since initiating their inaugural trial in 2018. Currently conducting five active trials, they have already completed eight investigations into androgenetic alopecia.
The Dawes Fretzin Clinical Research Group LLC in Indianapolis also deserves recognition for its efforts in advancing our understanding of this condition. With four ongoing clinical trials and ten all-time studies under their belt since starting research in 2016, they continue to impact the field positively. Additionally entering the scene is NW Dermatology & Research Center LLC based in Portland where four active androgenetic alopecia trials contribute towards overall scientific knowledge; however theirs remains relatively new having only begun documenting these investigations as recently as 2015.
Notably joining this group is Memorial Sloan Kettering Cancer Center once again demonstrating its versatility by delving into dermatological conditions such as androgenetic alopecia - three ongoing clinical tests further building upon three former experiments from inception during year 2014.These esteemed institutions symbolize hope for individuals grappling with hair loss due to genetic factors like male or female pattern baldness.For them it represents an opportunity not just restore confidence but open doors treatment options that may revolutionize future possibilities- highlighting how medical advancements can reshape lives beyond conventional expectations
Which are the best cities for androgenetic alopecia clinical trials?
For individuals seeking clinical trials for androgenetic alopecia, several cities emerge as frontrunners in research. New york, New York, leads the way with 14 active trials investigating treatments like Dupilumab, CTP-543, and Treatment Group. Portland, Oregon closely follows with 14 ongoing studies focusing on interventions such as Baricitinib and TDM-105795 topical solution. San Antonio, Texas ranks third with 13 active trials studying CTP-543 and Deucravacitinib Dose 1 among others. Across the country in Minneapolis, Minnesota, there are 12 ongoing trials examining PF-06651600 and Baricitinib alongside other potential treatments. Finally, Houston,Texas offers 11 active trials exploring options like Baricitinib and Deucravacitinib Dose 1 along with innovative interventions such as PAXMAN Orbis Scalp Cooler. These cities provide promising opportunities for those interested in participating in cutting-edge clinical research for combating androgenetic alopecia.
Which are the top treatments for androgenetic alopecia being explored in clinical trials?
Clinical trials are actively exploring various treatment options for androgenetic alopecia, a common form of hair loss. Among the top treatments being investigated are:
- PF-06651600: With three active trials dedicated to androgenetic alopecia, this drug has shown promise since its listing in 2016.
- Baricitinib: Listed in 2018, baricitinib is currently involved in two ongoing clinical trials for treating androgenetic alopecia.
- Dupilumab: Also listed in 2018, dupilumab is being studied in two active trials to determine its effectiveness against androgenetic alopecia.
As researchers delve deeper into these potential therapies, there is hope that new solutions may emerge to address the challenges posed by androgenetic alopecia.
What are the most recent clinical trials for androgenetic alopecia?
Exciting advancements in the field of androgenetic alopecia treatment are emerging from recent clinical trials. ADX-914, a promising experimental drug, has shown potential in Phase 2 studies for combating this condition. Farudodstat, Dupilumab, Oral Minoxidil, and TDM-105795 topical solution have also undergone Phase 2 trials with encouraging results. These innovative therapies offer new hope for individuals seeking effective treatments to address androgenetic alopecia's impact on hair loss. With further research and development underway, there is optimism for improved solutions to combat this common condition in the near future.
What androgenetic alopecia clinical trials were recently completed?
Several noteworthy clinical trials for androgenetic alopecia have recently reached completion, presenting promising developments in the search for effective treatments. In April 2022, LEO Pharma concluded a trial investigating Delgocitinib cream. Likewise, in February 2022, Suzhou Kintor Pharmaceutical Inc.'s GT20029 Gel study and Technoderma Medicines Inc.'s TDM-105795 trial were finished. Another TDM-105795 trial by Technoderma Medicines Inc., along with Concert Pharmaceuticals' CTP-543 investigation, wrapped up their respective studies in April 2021 and February 2021. Earlier milestones include Pfizer's Etrasimod trial completed in July 2020 and the University of Arizona's Keratinocyte growth factor study finalized in April 2020. These achievements underscore the dedication of researchers aiming to address the challenges posed by androgenetic alopecia while offering hope to individuals affected by this condition.